VAERS Explorer
Back to explore

Report #2896080

Received May 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
1 yrs
State
MN
Recovered
Unknown
Vaccinated
Apr 17, 2026
Onset
Apr 17, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HIBVHIB (ACTHIB)SANOFI PASTEURUNKUK230AAIM / LL

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

inappropriate use due to hcp not reconstituting product with the correct diluent with no reported adverse event; Initial information received on 24-Apr-2026 regarding an unsolicited valid non-serious case received from a health care professional. This case involves a 1-year-old male patient who received only the saline diluent component of Hib (Prp/T) Vaccine [Act-Hib] without reconstitution with the lyophilized component with no reported adverse event. The patient's past medical history, past drugs, vaccination(s), family history, concomitant medications were not provided. Concomitant medication(s) included pneumococcal vaccine conj 20v (CRM197) (PREVNAR 20). On 17-Apr-2026, the patient received only the saline diluent component of 0.5 mL (once) dose 1 of Hib (Prp/T) Vaccine, powder and solvent for solution for injection of standard strength (batch/lot number: UK230AA, expiry date: 30-Jun-2026) via intramuscular route in left thigh for immunization, without reconstituting it with the lyophilized component (Product preparation issue) (latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Other medications

Prevnar 20